Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Prostate
ARASENS
A randomized, double·blind, placebo·controlled Phase III study of ODM·201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone·sensitive prostate cancer.
Paris
PHILIPPE BEUZEBOC
Prostate
CARD (LPS14201)
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD).
Paris
PHILIPPE BEUZEBOC
Prostate
MK3475-365
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Paris
Prostate
PEACE 1 (GETUG-AFU 21)
A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.
Paris
FRANCESCO RICCI
Sein métastatique RH+
COMPLEEMENT-1
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
Paris, Saint-Cloud
PAUL-HENRI COTTU, FLORENCE LEREBOURS
Gynécologie - Ovaires
OReO
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.
Paris, Saint-Cloud
Sein métastatique RH+
PADA-1
Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients.
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, CORALINE DUBOT
Gynécologie - Ovaires
PiSARRO
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246.
Paris
PAUL-HENRI COTTU